ReviewJournal of thoracic disease2026
Vaping-related lung disease: a narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The use of vaping devices, or e-cigarettes, has increased substantially over the past two decades, particularly amongst children and young adults. Although these devices have been promoted as aids to smoking cessation, there is growing recognition that vaping may be associated with a range of adverse pulmonary and extra-pulmonary effects. Importantly, the long-term consequences of vaping on lung health remain poorly understood. In this review, we summarise current evidence regarding the pathophysiological effects and major clinical manifestations of vaping on the lungs. Additionally, we provide an overview of vaping epidemiology and the various products in use. Methods: We conducted a search of PubMed from inception to 30 Key Content and Findings: Vaping behaviour has steadily increased over the past decade and has now overtaken conventional cigarette smoking in the United Kingdom. Importantly, a significant proportion of users are children and young adults, many of whom have never previously smoked. The acute impacts of vaping were initially characterised by the emergence of e-cigarette or vaping product use-associated lung injury (EVALI), linked to vitamin E acetate (VEA) exposure. However, various manifestations of vaping-related lung disease have been reported, including pneumothorax, hypersensitivity pneumonitis, and bronchiolitis obliterans. Chronic respiratory symptoms (e.g., cough, dyspnoea, and wheeze) are common, though the long-term impact of vaping on lung function and the development of chronic lung disease remains uncertain. Conclusions: There is a spectrum of lung disease associated with vaping, extending beyond EVALI alone. As knowledge of the pathophysiological effects and clinical manifestations continues to grow, it is imperative that these devices are no longer viewed as 'safe'. Research into the long-term impacts of vaping is crucial to guide legislative policies, and to support evidence-based discussions with individuals regarding ongoing use of these devices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.